Article (Scientific journals)
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
James, W. P.; Caterson ID, I.D.; Coutinho, W. et al.
2010In New England Journal of Medicine, 363, p. 905-907
Peer Reviewed verified by ORBi
 

Files


Full Text
Effect of Sibutramine on Cardiovascular Outcomes.pdf
Publisher postprint (574.14 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Cardiovascular Diseases chemically induced; mortality; complications/epidemiology; Appetite Depressants adverse effects/; therapeutic use
Abstract :
[en] BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Disciplines :
Endocrinology, metabolism & nutrition
Cardiovascular & respiratory systems
Pharmacy, pharmacology & toxicology
Author, co-author :
James, W. P.
Caterson ID, I.D.
Coutinho, W.
Finer N, N.
Van Gaal, L.F.
Maggioni, A.P
Torp-Pedersen, C.
Sharma, A.M.
Shepherd, G.M.
Rode, R.A
Renz, C.L.
SCOUT Investigators.
Other collaborator :
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
Publication date :
2010
Journal title :
New England Journal of Medicine
ISSN :
0028-4793
eISSN :
1533-4406
Publisher :
Massachusetts Medical Society, Waltham, United States - Massachusetts
Volume :
363
Pages :
905-907
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 16 December 2010

Statistics


Number of views
84 (4 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
719
Scopus citations®
without self-citations
685
OpenCitations
 
625

Bibliography


Similar publications



Contact ORBi